Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Boucher

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Current Medical Research and Opinion|December 29, 2015
Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorderRoger S McIntyre, Rana Fayyad, Joan A Mackell, et al.
International Journal of Cell Biology|February 5, 2010
Determinants Present in the Receptor Carboxy Tail Are Responsible for Differences in Subtype-Specific Coupling of beta-Adrenergic Receptors to Phosphoinositide 3-KinaseJulie Simard, Matthieu Boucher, Rachel Massé, et al.
Expert Opinion on Pharmacotherapy|June 11, 2014
Desvenlafaxine for the treatment of major depressive disorderSusan G Kornstein, Roger S McIntyre, Michael E Thase, et al.
Expert Opinion on Therapeutic Targets|September 2, 2025
Role of serotonin in the neurobiology of attention-deficit/hyperactivity disorder: a systematic literature reviewStephen V Faraone, Caroline L Ward, Matthieu Boucher, et al.
Journal of Affective Disorders|April 2, 2017
Restoring function in major depressive disorder: A systematic reviewDavid V Sheehan, Kazuyuki Nakagome, Yuko Asami, et al.
Current Medical Research and Opinion|November 1, 2016
A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorderMichael Thase, Yuko Asami, Dalia Wajsbrot, et al.
Neuroscience and Biobehavioral Reviews|July 7, 2025
Role of serotonin in psychiatric and somatic comorbidities of attention-deficit/hyperactivity disorder: a systematic literature reviewStephen V Faraone, Caroline L Ward, Matthieu Boucher, et al.
The Primary Care Companion for CNS Disorders|July 3, 2015
An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive DisorderRoger S McIntyre, Rana S Fayyad, Christine J Guico-Pabia, et al.
The Primary Care Companion for CNS Disorders|December 9, 2015
A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/dRoger S McIntyre, Rana S Fayyad, Christine J Guico-Pabia, et al.
Biological Psychiatry|October 6, 2005
Apoptosis detected in the amygdala following myocardial infarction in the ratBoubacar Pasto Wann, Matthieu Boucher, Sevan Kaloustian, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|December 29, 2015
Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorderRoger S McIntyre, Rana Fayyad, Joan A Mackell, et al.
International Journal of Cell Biology|February 5, 2010
Determinants Present in the Receptor Carboxy Tail Are Responsible for Differences in Subtype-Specific Coupling of beta-Adrenergic Receptors to Phosphoinositide 3-KinaseJulie Simard, Matthieu Boucher, Rachel Massé, et al.
Expert Opinion on Pharmacotherapy|June 11, 2014
Desvenlafaxine for the treatment of major depressive disorderSusan G Kornstein, Roger S McIntyre, Michael E Thase, et al.
Expert Opinion on Therapeutic Targets|September 2, 2025
Role of serotonin in the neurobiology of attention-deficit/hyperactivity disorder: a systematic literature reviewStephen V Faraone, Caroline L Ward, Matthieu Boucher, et al.
Journal of Affective Disorders|April 2, 2017
Restoring function in major depressive disorder: A systematic reviewDavid V Sheehan, Kazuyuki Nakagome, Yuko Asami, et al.
Current Medical Research and Opinion|November 1, 2016
A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorderMichael Thase, Yuko Asami, Dalia Wajsbrot, et al.
Neuroscience and Biobehavioral Reviews|July 7, 2025
Role of serotonin in psychiatric and somatic comorbidities of attention-deficit/hyperactivity disorder: a systematic literature reviewStephen V Faraone, Caroline L Ward, Matthieu Boucher, et al.
The Primary Care Companion for CNS Disorders|July 3, 2015
An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive DisorderRoger S McIntyre, Rana S Fayyad, Christine J Guico-Pabia, et al.
The Primary Care Companion for CNS Disorders|December 9, 2015
A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/dRoger S McIntyre, Rana S Fayyad, Christine J Guico-Pabia, et al.
Biological Psychiatry|October 6, 2005
Apoptosis detected in the amygdala following myocardial infarction in the ratBoubacar Pasto Wann, Matthieu Boucher, Sevan Kaloustian, et al.
Pageof 5